Survival and prognostic factors in patients with Non-Small Cell Lung Cancer treated in private health care

Araujo, Luiz H.; Baldotto, Clarissa; Zukin, Mauro; Vieira, Fernando Meton de Alencar Câmara; Victorino, Ana Paula; Rocha, Viviani Ribeiro; Helal, R. C.; Salem, Jonas Hauben; Teich, Nelson; Ferreira, Carlos Gil

doi:10.1590/1809-4503201400040017

Cited by 20 publications

(26 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The magnitudes and directions of the estimated effects related to these factors in the present study are consistent with those reported in other studies and will be addressed below 6 18 , 19 …”

Section: Discussionsupporting

confidence: 90%

“…A review of the literature revealed two survival studies of patients with non-small cell lung cancer, both of which were conducted in the city of Rio de Janeiro, Brazil: one in a public hospital, in which 60-month survival probabilities were estimated 6 ; and one in a private clinic, 19 in which 24-month survival probabilities were estimated.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Factors associated with disease-specific survival of patients with non-small cell lung cancer

2016

View full text Add to dashboard Cite

Objective:Lung cancer is a global public health problem and is associated with high mortality. Lung cancer could be largely avoided by reducing the prevalence of smoking. The objective of this study was to analyze the effects of social, behavioral, and clinical factors on the survival time of patients with non-small cell lung cancer treated at Cancer Hospital I of the José Alencar Gomes da Silva National Cancer Institute, located in the city of Rio de Janeiro, Brazil, between 2000 and 2003. Methods:This was a retrospective hospital cohort study involving 1,194 patients. The 60-month disease-specific survival probabilities were calculated with the Kaplan-Meier method for three stage groups. The importance of the studied factors was assessed with a hierarchical theoretical model after adjustment by Cox multiple regression. Results:The estimated 60-month specific-disease lethality rate was 86.0%. The 60-month disease-specific survival probability ranged from 25.0% (stages I/II) to 2.5% (stage IV). The performance status, the intention to treat, and the initial treatment modality were the major prognostic factors identified in the study population. Conclusions:In this cohort of patients, the disease-specific survival probabilities were extremely low. We identified no factors that could be modified after the diagnosis in order to improve survival. Primary prevention, such as reducing the prevalence of smoking, is still the best method to reduce the number of people who will suffer the consequences of lung cancer.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Factors associated with disease-specific survival of patients with non-small cell lung cancer

2016

View full text Add to dashboard Cite

show abstract

“…Prior studies in Brazil have reported median OS similar to our findings (Araujo et al., 2014; Younes, Pereira, Fares, & Gross, 2011). The median OS of 25.5 months in our Taiwanese cohort could be the result of frequent and appropriate therapy with EGFR TKIs for patients with EGFR ‐positive status, since gefitinib was approved for first‐line therapy of EGFR ‐positive NSCLC in Taiwan in June 2011.…”

Section: Discussionmentioning

confidence: 99%

Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study

et al. 2017

View full text Add to dashboard Cite

The aim of this multinational retrospective cohort study, conducted at academic and community oncology centres, was to describe real‐world treatment patterns for patients with a confirmed diagnosis of advanced/metastatic (stage IIIB/IV) non‐small cell lung cancer (NSCLC) who initiated first‐line systemic therapy from January 2011 through June 2014. The study included 1265 patients in Italy, Spain, Germany, Australia, Korea, Taiwan and Brazil. The proportion of patients with squamous versus non‐squamous NSCLC was approximately 20% versus 75%, and associated patient demographic characteristics were similar in all countries, excepting race. Patients with squamous NSCLC were predominantly male and current/ex‐smokers. Biomarker tests were performed for the majority of patients with non‐squamous NSCLC, ranging from 54% (Brazil) to 91% in Taiwan, where, of those tested, 68% with non‐squamous NSCLC had positive epidermal growth factor receptor (EGFR)‐mutation status; in other countries the EGFR‐positive percentages ranged from 17% (Spain/Brazil) to 40% (Korea). Platinum‐based regimens were the most common first‐line therapy in all countries except Taiwan, where gefitinib was the most common first‐line agent. Median overall survival ranged from 9.3 months (Brazil) to 25.5 months (Taiwan). The diagnostic and treatment patterns recorded in this study were heterogeneous but largely in line with NSCLC guidelines during the study period.

show abstract

“…A study that aimed to describe the characteristics, treatments and survival of lung cancer patients identified that 59.9% of the patients received palliative therapy. It is reiterated that, of those mentioned, most of the 236 patients presented diagnosis in advanced stages (6) . In this study, all of the patients had clinical stage IV, and lung cancer cases accounted for 6.5%.…”

Section: Alcohol and Tobacco Consumption Became A Constantmentioning

confidence: 98%

“…Once called "individual risk factors," they now have broader approaches that favor the profile of access to public policies, consumption patterns and social interaction networks (5) . Despite major advances in cancer treatment, healing is not always possible and the result is shown in the ascending slope of incidence and mortality of cancer cases in Brazil (6) . With this scenario, the World Health Organization (WHO) increasingly recommends that the approach to people in later life be programmed and planned in order to comprehensively meet the multiplicity of problems presented (7) .…”

Section: Introductionmentioning

confidence: 99%

Palliative therapy in adults with cancer: a cross-sectional study

et al. 2018

View full text Add to dashboard Cite

Objective: To characterize the socioeconomic and clinical profi le of adult cancer patients in palliative therapy. Method: Cross-sectional study in an oncology hospital in Paraná, with 124 adult patients who started palliative therapy in the period from Jan. 2 to June 30, 2015. Results: Of the participating population, 60.5% were women, 68.5% white, 48.4% married, 72.6% catholic and with income of one to two minimum wages. Non-smokers, 45.2%, non-alcoholics 75%, and 92% had Performance Status 1 and 2. The predominant primary diagnosis was breast cancer, with previous chemotherapy and radiotherapy. The sites of metastasis were lung/mediastinum/bronchi and lymph nodes. Conclusion: The socioeconomic and clinical context characterized the profi le of adult patients in palliative therapy. The demand arising from the increase in cases of advanced cancer requires nursing care at all stages of treatment. Descriptors: Cancer; Socioeconomic Factors; Palliative Care; Oncology Nursing; Adult. RESUMO Objetivo: caracterizar o perfi l socioeconômico e clínico dos pacientes oncológicos adultos na terapêutica paliativa. Método: estudo transversal realizado em um hospital de oncologia no Paraná, com 124 pacientes adultos que iniciaram a terapêutica paliativa no período 2 de janeiro a 30 de junho de 2015. Resultados: da população participante, 60,5% era do sexo feminino, 68,5% branca, 48,4% casada, 72,6% de religião católica e com renda de um a dois salários mínimos. Não tabagistas, 45,2%, 75% não etilistas, e 92% apresentam Performance Status 1 e 2. O diagnóstico do câncer primário prevalente foi mama, com tratamento prévio de quimioterapia e radioterapia. Os locais de metástase foram pulmão/mediastino/brônquios e linfonodos. Conclusão: o contexto socioeconômico e clínico apresentado caracterizou o perfi l dos pacientes adultos na terapêutica paliativa. A demanda que advém do aumento dos casos de câncer avançado requer a atenção da enfermagem em todas as fases do tratamento. Descritores: Câncer; Fatores Socioeconômicos; Tratamento Paliativo; Enfermagem Oncológica; Adulto. RESUMEN Objetivo: caracterizar el perfi l socioeconómico y clínico de los pacientes oncológicos adultos en la terapéutica paliativa. Método: estudio transversal realizado en un hospital de oncología en Paraná, Brasil, con 124 pacientes adultos que iniciaron la terapéutica paliativa desde el 2 de enero hasta el 30 de junio de 2015. Resultados: de la población participante, 60,5% era del sexo femenino; 68,5% blanca; 48,4% casada; y 72,6% de religión católica y con renda de un a dos salarios mínimos. No fumadores, 45,2%; 75% no alcohólicos; y 92% presentan Escala de Rendimiento de Karnofsky 1 y 2. El diagnóstico del cáncer primario prevalente fue de mama, con tratamiento previo de quimioterapia y radioterapia. Los locales de metástasis fueron pulmón/mediastino/bronquios y ganglios linfáticos. Conclusión: el contexto socioeconómico y clínico presentado caracterizó el perfi l de los pacientes adultos en la terapéutica paliativa. La demanda que resulta del aum...

show abstract

Survival and prognostic factors in patients with Non-Small Cell Lung Cancer treated in private health care

Abstract: The outcomes described are favorably similar to the current literature from developed countries. Besides the better access to health care in the private insurance scenario, most patients are still diagnosed in late stages.

Cited by 20 publications

References 15 publications

Factors associated with disease-specific survival of patients with non-small cell lung cancer

Factors associated with disease-specific survival of patients with non-small cell lung cancer

Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study

Palliative therapy in adults with cancer: a cross-sectional study

Contact Info

Product

Resources

About